{
    "title": "111_s1674",
    "content": "The Act titled \"Improving Access to Clinical Trials Act of 2009\" acknowledges the importance of clinical trial research for medical advancements, especially for rare diseases. It highlights the challenges of enrolling participants in studies and allows sponsors to provide payments for out-of-pocket costs and time commitment. The Act \"Improving Access to Clinical Trials Act of 2009\" recognizes the significance of clinical trial research for rare diseases. Compensation for participation in trials may hinder enrollment if it affects eligibility for benefits like Supplemental Security Income and Medicaid. This can make research on new treatments and cures for rare diseases challenging. The Act \"Improving Access to Clinical Trials Act of 2009\" allows individuals with rare diseases to exclude the first $2,000 received as compensation for participating in a clinical trial from their income for the calendar year. This applies to trials approved by an institutional review board to protect human subjects in research. The Act \"Improving Access to Clinical Trials Act of 2009\" allows individuals with rare diseases to exclude compensation from income for participating in clinical trials approved by an institutional review board to protect human subjects in research. The Act \"Improving Access to Clinical Trials Act of 2009\" allows individuals with rare diseases to exclude the first $2,000 of compensation from income for participating in clinical trials testing treatments for rare diseases or conditions under Medicaid. The Act \"Improving Access to Clinical Trials Act of 2009\" includes amendments to U.S.C. 1396a(a)(17), with an effective date based on final regulations or 180 days after enactment. A sunset provision repeals the Act and its amendments after 5 years. A study by the Comptroller General will evaluate the Act's impact on SSI enrollment within 36 months of its effective date. The Social Security Act requires a study on SSI beneficiaries participating in clinical trials for rare diseases or conditions. The study will analyze the percentage of SSI beneficiaries in trials before and after the Act, compensation amounts, participation ability, and other relevant matters. The Comptroller General must submit a report within 12 months of completing the study. The Comptroller General must submit a report to Congress containing the results of a study on SSI beneficiaries participating in clinical trials for rare diseases, along with recommendations for legislation and administrative action. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}